Construction of novel platforms for herpes simplex virus attenuated vaccines
| Project/Area Number |
26670220
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | HSV / 宿主免疫回避 / 感染制御 / 制御 |
|---|
| Outline of Final Research Achievements |
We have constructed novel live attenuated herpes simplex virus (HSV) vaccines. The constructed vaccines exhibited more vaccine efficacy than a control live attenuated HSV vaccine, TK-deficient mutant virus. In addition, we identified novel HSV proteins that inhibit host immune responses. One of the HSV proteins inhibited induction of proinfalamatory cytokines, which are known to control HSV infection in vivo, by interacting with a host cellular protein that regulates the induction of the proinflamatory cytokines.
|
Report
(4 results)
Research Products
(11 results)
